<DOC>
	<DOCNO>NCT02677116</DOCNO>
	<brief_summary>The main purpose study evaluate safety different dos olaratumab determine dose use future pediatric study . The present study open child advance cancer cancer spread another part body . The study two part . In part , specific dose olaratumab give 21 day , follow one three standard chemotherapy regimen . Participants enroll one part .</brief_summary>
	<brief_title>A Study Olaratumab Alone Combination With Standard Chemotherapies Children With Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>The participant must histological cytological evidence diagnosis solid tumor , exclude lymphoma melanoma , include central nervous system ( CNS ) tumor , relapse refractory , amenable curative treatment . The participant presence measurable and/or nonmeasurable evaluable disease define Response Evaluation Criteria In Solid Tumors ( RECIST Version 1.1 ) . Response Assessment NeuroOncology ( RANO ) Criteria Macdonald Criteria use CNS tumor . The participant Lansky ( &lt; 16 year age ) Karnofsky ( ≥16 year age ) performance score least 50 . The participant adequate hematologic , organ , coagulation function ≤2 week ( 14 day ) prior first dose study drug : Absolute neutrophil count ( ANC ) ≥750 cubic millimeter ( mm³ ) Platelets ≥75,000/mm³ Hemoglobin ≥8 gram per deciliter ( g/dL ) Total bilirubin ( sum conjugate + unconjugated ) ≤1.5 x upper limit normal ( ULN ) age Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤3.0 x ULN Serum creatinine base age/gender Adequate coagulation function define International Normalized Ratio ≤1.5 prothrombin time ≤1.5 x ULN , partial thromboplastin time ≤1.5 x ULN Both female male participant childbearing potential must agree use highly effective contraceptive precaution trial 3 month follow last dose study drug , appropriate . Participants must fully recover acute toxic effect prior anticancer therapy must adhere posttreatment condition follow : Myelosuppressive chemotherapy Hematopoietic growth factor Biologic ( antineoplastic agent ) Antibody therapy Radiation Stem cell infusion without traumatic brain injury Corticosteroids Have receive treatment within 21 day initial dose study drug investigational product nonapproved use drug device concurrently enrol type medical research judge scientifically medically compatible study . Participants bone marrow solid organ transplant exclude . The participant active fungal , bacterial , and/or know severe viral infection include human immunodeficiency virus ( HIV ) viral ( A , B , C ) hepatitis ( screen require ) . Female participant pregnant breastfeeding exclude . If participant enrol doxorubicin combination arm , leave ventricular dysfunction ( LVEF &lt; 50 % ) shorten fraction &lt; 27 % echocardiogram ( either multigated acquisition [ MUGA ] echocardiogram [ ECHO ] require , ) . Participants receive prior anthracycline therapy participant enrol doxorubicin combination arm .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>